Adjuvant Therapy of Breast Cancer

  • I. Craig Henderson

Part of the Cancer Treatment and Research book series (CTAR, volume 60)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Rationale and Methods for Studying Adjuvant Systemic Therapy

  3. Results of Clinical Studies

    1. Front Matter
      Pages 55-55
    2. I. Craig Henderson
      Pages 57-68
    3. Maureen E. Trudeau, Kathleen I. Pritchard
      Pages 69-114
    4. Nancy E. Davidson, Martin D. Abeloff
      Pages 115-145
    5. David L. Ahmann
      Pages 147-158
  4. Special Problems

    1. Front Matter
      Pages 159-159
    2. Gary M. Clark, William L. McGuire
      Pages 161-187
    3. Richard D. Gelber, Aron Goldhirsch
      Pages 189-206
    4. Rebecca Johnson Irvin, John G. Kuhn
      Pages 207-222
    5. Abram Recht, Daniel F. Hayes, Jay R. Harris
      Pages 223-237
    6. Rowan T. Chlebowski
      Pages 239-253
  5. Future Directions

    1. Front Matter
      Pages 255-255
    2. F. Andrew Dorr, Michael A. Friedman
      Pages 257-278
    3. William C. Wood
      Pages 279-291
    4. James B. Breitmeyer
      Pages 331-356
    5. Umberto Veronesi, Alberto Costa
      Pages 357-367
  6. Back Matter
    Pages 369-464

About this book


The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world­ wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu­ lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy.


adjuvant therapy cell clinical trial immunotherapy prevention radiotherapy surgery systemic therapy

Editors and affiliations

  • I. Craig Henderson
    • 1
  1. 1.University of CaliforniaSan FranciscoUSA

Bibliographic information

  • DOI
  • Copyright Information Kluwer Academic Publishers 1992
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6550-1
  • Online ISBN 978-1-4615-3496-9
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site